Replies to post #494098 on Anavex Life Sciences Corp (AVXL)

[Investor2014]

The data analysis methodology and results Anavex presents still have to be verifiable by EMA - if that does not turn out acceptable all the rest doesn't matter.

Let's hope nobody cooked the books on that data - and keep in mind that peer reviewers do not have access to the raw data, only what is written in the paper. Whereas, the CHMP team do have or require access to it all!

[La Flaca]

Doubt any on these professionals would "cook" the books. I'd say their reviews weren't cursory.

[La Flaca]

Dr. Marwan N. Sabbagh: Chairman of Anavex's Scientific Advisory Board and a behavioral neurologist in the Alzheimer's and Memory Disorders Program at Barrow Neurological Institute.
Dr. Andrew J. Cole: Director of the MGH Epilepsy Service, Chief of the Division of Clinical Neurophysiology and Epilepsy, and Professor of Neurology at Harvard Medical School.
Dr. Timo Grimmer: Served as National Coordinating Investigator for the ANAVEX®2-73 (blarcamesine) Phase 2b/3 study and is head of the Centre for Cognitive Disorders at the Technical University of Munich, School of Medicine.
Dr. Audrey Gabelle: Professor of Neurology and researcher at the Montpellier Institute of Neurosciences.
Dr. Harald Hampel: Professor and AXA Research Fund Chair at Sorbonne Universities' Pierre and Marie Curie University in Paris.